Journal
DERMATOLOGY
Volume 215, Issue 3, Pages 245-251Publisher
KARGER
DOI: 10.1159/000106584
Keywords
ulcerative colitis; Crohn's disease; infliximab; pyoderma gangrenosum; tumor necrosis factor alpha
Categories
Ask authors/readers for more resources
We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases. Copyright (C) 2007 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available